GlassScriptPhysician profile
Robert T Wang
NPI 1235293648
$2,364.13
in general payments reported to CMS, 2019-2025
23 companies · $469 in 2025
The $469 reported for 2025 was more than what 78% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $54.88 · 2021: $373 · 2022: $574 · 2023: $339 · 2024: $319 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $679.56 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $603.47 | 2019-2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $293.63 | 2023-2025 | Nuedexta, Rexulti |
| Harrow Eye, LLC | $100.93 | 2025 | Ilevro |
| Dexcom, INC. | $99.27 | 2024 | Dexcom G6 Transmitter |
| Akebia Therapeutics INC | $80.98 | 2025 | Vafseo |
| Astrazeneca Pharmaceuticals LP | $68.46 | 2023-2024 | Airsupra, Farxiga |
| Ibsa Pharma INC. | $40.01 | 2025 | Licart, Flector, Tirosint |
| Eisai INC. | $39.76 | 2024 | |
| Electromed, INC. | $34.61 | 2023 | Smartvest |
| Ardelyx, INC. | $34.25 | 2025 | Ibsrela |
| Exact Sciences Corporation | $31.77 | 2024 | Cologuard Collection Kit |
| Tanabe Pharma America, INC. | $29.47 | 2025 | Radicava |
| Madrigal Pharmaceuticals | $29.18 | 2025 | Rezdiffra |
| Sequel Med Tech, LLC | $26.91 | 2025 | Twiist |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $25.57 | 2023 | Lybalvi |
| Amgen INC. | $24.51 | 2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $24.41 | 2021 | |
| Abbott Laboratories | $23.43 | 2024 | Eterna |
| Lilly USA, LLC | $20.68 | 2025 | Jardiance |
| Pfizer INC. | $18.68 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.58 | 2021 | |
| Luye Pharma (USA) LTD. | $17.01 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.